Compare Inovio Pharmaceuticals Inc (INO) vs Iron Mountain Inc (IRM) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

Iron Mountain (IRM) trades at $125.56, up 1.41% today, near its recent highs. The stock shows strong momentum with a bullish technical signal and consistent earnings beats. Revenue grew to $6.90B in 2025, though net margins are thin at 3.76%. High debt levels and a P/E of 135.03 present valuation concerns, but analyst consensus is bullish with a $140.50 price target. Recent news highlights institutional activity and data center growth potential.

Outlook remains positive driven by recurring revenue streams and data center expansion, but investors face risks from elevated leverage and interest expenses. The stock offers growth exposure with a dividend, yet requires monitoring of debt management and competitive pressures in information services.